Principal Investigator: Robert Innis
B.S., Yale College, 1974, Molec. Biophysics & Biochemistry (1970 - 1974)
M.D., Johns Hopkins School of Medicine, 1978 (1974 - 1978)
Ph.D., Pharmacology, Johns Hopkins School of Medicine, 1981 (1976 - 1980)
Nuclear Medicine, six-month training for Authorized User (10 CFR 35) of radiopharmaceuticals in human subjects (1995)
1980-1984 Resident in Psychiatry, Yale University (1980 - 1984)
1984-1990 Assistant Professor, Dept. Psychiatry, Yale University
1990-1994 Associate Professor, Yale Dept. Psychiatry
1994-2001 Appointment with tenure, Yale University
1996-2001 Professor of Psychiatry and Pharmacology, Yale University
2001- Chief, Molecular Imaging Branch, NIMH
My laboratory develops and uses positron emission tomographic (PET) radioligands to study pathophysiology in several neuropsychiatric disorders. Working in close collaboration with the radiochemistry laboratory of Dr. Victor Pike, we use in vivo imaging to evaluate novel PET radioligands, first in animals, then in healthy human subjects, and finally in patients. My laboratory has multidisciplinary expertise in pharmacology, animal experimentation, clinical neuroscience, digital image analysis, and human evaluation of investigational radiopharmaceuticals. In addition to traditional receptor targets, we use radiolabeled probes for in vivo imaging of intracellular signal transduction (e.g., cAMP phosphodiesterase), gene expression (e.g., dopamine transporters expressed on transplanted embryonic stem cells), and a mitochondrial protein that is a marker for inflammatory cells (activated microglia and macrophages).
A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation . Kreisl WC, Jenko KJ, Hines CS, Hyoung Lyoo C, Corona W, Morse CL, Zoghbi SS, Hyde T, Kleinman JE, Pike VW, McMahon FJ, Innis RB; Biomarkers Consortium PET Radioligand Project Team. J Cereb Blood Flow Metab. 2013 Jan;33(1):53-8. doi: 10.1038/jcbfm.2012.131. Epub 2012 Sep 12. PMID: 22968319.
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder . Fujita M, Hines CS, Zoghbi SS, Mallinger AG, Dickstein LP, Liow JS, Zhang Y, Pike VW, Drevets WC, Innis RB, Zarate CA Jr. Biol Psychiatry. 2012 Oct 1;72(7):548-54. doi: 10.1016/j.biopsych.2012.04.030. Epub 2012 Jun 5. PMID: 22677471.
Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers . Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB. Mol Psychiatry. 2012 Jun;17(6):642-9. doi: 10.1038/mp.2011.82. Epub 2011 Jul 12. PMID: 21747398.
Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy . Hirvonen J, Kreisl WC, Fujita M, Dustin I, Khan O, Appel S, Zhang Y, Morse C, Pike VW, Innis RB, Theodore WH. J Nucl Med. 2012 Feb;53(2):234-40. doi: 10.2967/jnumed.111.091694. Epub 2012 Jan 11. PMID: 22238156.
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET . Kannan P, Brimacombe KR, Kreisl WC, Liow JS, Zoghbi SS, Telu S, Zhang Y, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2593-8. doi: 10.1073/pnas.1014641108. Epub 2011 Jan 24. PMID: 21262843.
Magnuson Clinical Center, Room B1D43J, MSC 1026
BETHESDA, MD 20814
Phone: +1 301 594 1368
Fax: +1 301 480 3610